Aydah AlAwadhi, Consultant Medical Oncologist and Division Chair of Hematology and Oncology Department at Sheikh Shakbout Medical City, Abu Dhabi, shared a post on LinkedIn:
“PATINA Trial | Published in NEJM
Phase 3 data show that adding palbociclib to maintenance anti-HER2 plus endocrine therapy in HR+/HER2+ metastatic breast cancer significantly improves outcomes:
- Median PFS: 44.3 months vs 29.1 months
- Absolute benefit: ~15 months
- No compromise in quality of life
Why this matters:
These results reinforce a new standard of care that should be offered to eligible patients, highlighting how integrating CDK4/6 inhibition into HER2-directed maintenance strategies can meaningfully extend disease control while preserving patient well-being.
Congratulations to Otto Metzger and the entire PATINA trial team for this outstanding scientific achievement.”
Title: Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Authors: Otto Metzger, Sumithra Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Travis Dockter, Xavier Gonzàlez Farré, Prudence A. Francis, Filipa Lynce, Jane Lanzillotti, Carter DuFrane, Anna Wall, Carrie Strand, Ian Krop, Ines Vaz-Luis, Debu Tripathy, Sherene Loi, Aleix Prat, Matthew Goetz, Santiago Escrivá-de-Romaní, David Porter, Jennifer Spoenlein, Daniel G. Stover, Sagar Sardesai, Pierre Heudel, Maria Koehler, Cynthia Huang Bartlett, Ariadna Holynskyj, Prashanth Gopalakrishna, Eric Gauthier, Suzette Delaloge, Kathy Miller, Eric P. Winer, Luca Gianni, Ann H. Partridge, Angela DeMichele, Lisa A. Carey
Read the Full Article on NEJM
More posts featuring Aydah AlAwadhi.
